Zomedica Expands TRUVIEW(R) and TRUFORMA(R) Intellectual Property Portfolio with Four Newly Issued U.S. Patents
Zomedica (OTCQB:ZOMDF) has strengthened its intellectual property portfolio with four new U.S. patents for its TRUVIEW and TRUFORMA diagnostic platforms. Three patents relate to the TRUVIEW Microscope's automated slide processing systems, while the fourth patent protects acoustic wave sensor technology with crowding agents.
The company now holds 83 U.S. patents and 145 international patents, along with 37 U.S. and 116 foreign trademarks. These innovations position Zomedica to compete in the veterinary diagnostics market, currently valued at $8-11 billion and projected to reach $17-22 billion by 2030-2032, growing at a 9-11% CAGR.
Zomedica (OTCQB:ZOMDF) ha rafforzato il suo portafoglio di proprietà intellettuale con quattro nuovi brevetti statunitensi per le sue piattaforme diagnostiche TRUVIEW e TRUFORMA. Tre brevetti riguardano i sistemi automatizzati di elaborazione delle vetrine del microscopio TRUVIEW, mentre il quarto brevetto protegge la tecnologia del sensore ad onde acustiche con agenti di affollamento.
L'azienda possiede ora 83 brevetti statunitensi e 145 brevetti internazionali, insieme a 37 marchi statunitensi e 116 marchi esteri. Queste innovazioni posizionano Zomedica per competere nel mercato della diagnostica veterinaria, attualmente valutato tra 8-11 miliardi di dollari e previsto d’atteggere 17-22 miliardi di dollari entro il 2030-2032, crescendo a un tasso di crescita annuo composto (CAGR) del 9-11%.
Zomedica (OTCQB:ZOMDF) ha fortalecido su cartera de propiedad intelectual con cuatro nuevas patentes estadounidenses para sus plataformas de diagnóstico TRUVIEW y TRUFORMA. Tres patentes se refieren a los sistemas automatizados de procesamiento de portaobjetos del Microscopio TRUVIEW, mientras que la cuarta patente protege la tecnología de sensores de onda acústica con agentes de densidad.
La compañía posee ahora 83 patentes en Estados Unidos y 145 patentes internacionales, junto con 37 marcas estadounidenses y 116 marcas extranjeras. Estas innovaciones sitúan a Zomedica para competir en el mercado de diagnósticos veterinarios, valorado actualmente en 8-11 mil millones de dólares y con pronóstico de alcanzar 17-22 mil millones de dólares para 2030-2032, creciendo a una tasa CAGR del 9-11%.
Zomedica (OTCQB:ZOMDF)는 TRUVIEW 및 TRUFORMA 진단 플랫폼에 대해 미국 특허 4건으로 지적 재산 포트폴리오를 강화했습니다. 3건의 특허는 TRUVIEW Microscope의 자동 슬라이드 처리 시스템과 관련이 있으며, 네 번째 특허는 어쿠스틱 웨이브 센서 기술을 crowding agents와 함께 보호합니다.
회사는 현재 미국 특허 83건과 국제 특허 145건, 더불어 미국 상표 37건과 해외 상표 116건을 보유하고 있습니다. 이러한 혁신은 Zomedica가 현재 80억-110억 달러 규모로 평가되는 수의학 진단 시장에서 경쟁할 수 있도록 하며, 2030-2032년까지 170억-220억 달러에 이를 것으로 전망되며, CAGR은 9-11%로 성장할 것으로 예상됩니다.
Zomedica (OTCQB:ZOMDF) a renforcé son portefeuille de propriété intellectuelle avec quatre nouveaux brevets américains pour ses plateformes diagnostiques TRUVIEW et TRUFORMA. Trois brevets concernent les systèmes automatisés de traitement des lames du TRUVIEW Microscope, tandis que le quatrième brevet protège la technologie de capteurs d'ondes acoustiques avec des agents de congestion.
L'entreprise détient désormais 83 brevets américains et 145 brevets internationaux, ainsi que 37 marques américaines et 116 marques étrangères. Ces innovations positionnent Zomedica pour concurrencer sur le marché des diagnostics vétérinaires, actuellement évalué à 8-11 milliards de dollars et prévu d’atteindre 17-22 milliards de dollars d’ici 2030-2032, avec une croissance annuelle composée (CAGR) de 9-11%.
Zomedica (OTCQB:ZOMDF) hat sein Portfolio an geistigem Eigentum mit vier neuen US-Patenten für die TRUVIEW- und TRUFORMA-Diagnoseplattformen gestärkt. Drei Patente beziehen sich auf die automatisierten Probenbearbeitungssysteme des TRUVIEW-Mikroskops, während das vierte Patent die Akustikwellen-Sensor-Technologie mit Crowding-Agenten schützt.
Das Unternehmen hält nun 83 US-Patente und 145 internationale Patente sowie 37 US- und 116 ausländische Marken. Diese Innovationen positionieren Zomedica, um im Tierdiagnostikmarkt zu konkurrieren, der derzeit auf 8–11 Milliarden USD geschätzt wird und voraussichtlich bis 2030–2032 17–22 Milliarden USD erreichen soll, bei einer CAGR von 9–11%.
زوميديا (OTCQB:ZOMDF) عزّزت محفظة الملكية الفكرية الخاصة بها بــ أربع براءات اختراع أمريكية جديدة لمنصتي TRUVIEW وTRUFORMA التشخيصيتين. تتعلق ثلاث براءات بنظم المعالجة الآلية لشرائح جهاز TRUVIEW Microscope، بينما تحمي البراءة الرابعة تكنولوجيا مستشعر الموجة الصوتية مع عوامل الازدحام.
تمتلك الشركة الآن 83 براءة اختراع أمريكية و145 براءة اختراع دولية، إلى جانب 37 علامة تجارية أمريكية و116 علامة تجارية أجنبية. هذه الابتكارات تضع Zomedica في موقع المنافسة في سوق تشخيصات الحيوانات الأليفة، الذي يقدر حاليًا بـ 8-11 مليار دولار ومن المتوقع أن يصل إلى 17-22 مليار دولار بحلول 2030-2032، بنمو سنوي مركب قدره 9-11%.
Zomedica (OTCQB:ZOMDF) 通过四项新的美国专利强化了其知识产权组合，涉及其 TRUVIEW 与 TRUFORMA 诊断平台。三项专利涉及 TRUVIEW 显微镜的自动载玻片处理系统，第四项专利保护带有拥挤剂的声波传感器技术。
公司现拥有 83项美国专利和145项国际专利，以及 37项美国商标和116项国外商标。这些创新将使 Zomedica 在兽用诊断市场具备竞争力，该市场当前估值为 80-110亿美元，预计到 2030-2032 年将达到 170-220亿美元，CAGR 达到 9-11%。
- None.
- None.
Insights
Zomedica strengthens market position with four strategic patents protecting innovative veterinary diagnostic technologies in $8-11B market.
Zomedica's acquisition of four new U.S. patents represents a significant strengthening of their intellectual property position in the veterinary diagnostics space. The company now holds an impressive portfolio of 228 patents and 153 trademarks globally, creating substantial barriers to entry for competitors.
Three of the patents extend protection for the TRUVIEW Microscope system, covering automated slide preparation and processing technologies. These innovations address a critical pain point in veterinary diagnostics—inconsistent manual slide preparation that can compromise test accuracy. By automating this process with micro-stream fluid dispensing and integrated imaging capabilities, Zomedica is solving a fundamental workflow challenge.
The fourth patent, the "Crowded Sensor" technology for TRUFORMA, is particularly noteworthy. This acoustic wave sensor enhanced with crowding agents solves the problem of analyte saturation by slowing binding kinetics. This creates a longer detection window and enables multiplexed detection of both high and low-abundance biomarkers in a single channel—a significant technical advancement that could improve diagnostic accuracy.
The strategic value of these patents is amplified by the market opportunity. The veterinary diagnostics sector is projected to grow from
This patent expansion demonstrates Zomedica's commitment to R&D investment and suggests the company is executing a methodical long-term strategy to build sustainable competitive advantages in veterinary point-of-care diagnostics.
Intellectual property portfolio now includes 228 Patents and 153 Trademarks providing robust protection for the Company's product platforms in the rapidly growing multi-billion dollar veterinary diagnostics market
ANN ARBOR, MI / ACCESS Newswire / September 18, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced the issuance of four additional U.S. patents protecting its TRUVIEW and TRUFORMA diagnostic platforms.
These new patents significantly strengthen Zomedica's intellectual property portfolio and enhance the Company's ability to compete and capture share in the rapidly expanding veterinary diagnostics market-currently valued at
The United States Patent and Trademark Office recently issued patents numbered 12,405,192 B2, 12,399,092 B2, and 12,385,815 related to the TRUVIEW Microscope.. These patents are a continuation of U.S. Patent No. 11,422,073, "Methods and Systems for Slide Processing," and cover proprietary automated systems that prepare and process diagnostic slides with precision.
The TRUVIEW system utilizes micro-stream fluid dispensing, automated slide smearing, and integrated imaging to deliver consistent, laboratory-quality results at the point of care.
On September 9, 2025, Zomedica was also issued U.S. Patent No. 12,411,110 B2, "Crowded Sensor." This patent protects breakthrough acoustic wave sensor devices enhanced with crowding agents that slow analyte binding kinetics. By extending the window for detection, the technology may provide more accurate results and prevent saturation in high-concentration samples. This can facilitate multiplexed detection of both high- and low-abundance biomarkers in a single channel.
With the addition of these patents, Zomedica now holds a total of 83 U.S. patents and 145 international patents, with 37 U.S. and 116 foreign trademarks, strengthening the Company's market position. The Company additionally has patent applications pending in the U.S. and abroad.
"These latest patents showcase Zomedica's ability to deliver innovation that creates value across the diagnostics spectrum," commented Ashley Wood, PhD, Zomedica's Vice President of Research & Development. "With patents protecting both the mechanics of slide preparation and the biochemistry of analyte detection, the TRUVIEW and TRUFORMA platforms are positioned as category-defining solutions in veterinary diagnostics. In a diagnostics market approaching
Karen DeHann-Fuller, General Counsel of Zomedica, added: "Zomedica's expanding intellectual property estate reflects the foresight of our R&D investments and legal strategy. By securing comprehensive protections for TRUVIEW and TRUFORMA, we are reinforcing our leadership position in veterinary diagnostics. These protections enhance the durability of our market advantage for years to come."
Global demand for faster, more accurate veterinary testing solutions is rising sharply. TRUVIEW and TRUFORMA's patented technologies directly address longstanding industry challenges, including sample degradation, manual slide preparation variability, and limited sensor performance. By standardizing preparation, automating processing, and enhancing biomarker quantification, Zomedica is positioned to capture a larger share of this high-growth market while improving diagnostic accuracy and outcomes for veterinarians and pet owners worldwide.
For more information on TRUVIEW and TRUFORMA and Zomedica's innovation pipeline, please visit www.zomedica.com
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on ACCESS Newswire
FAQ
What new patents did Zomedica (ZOMDF) receive in September 2025?
How many patents does Zomedica currently hold globally?
What is the projected market size for veterinary diagnostics by 2030-2032?
How do Zomedica's TRUVIEW and TRUFORMA technologies improve veterinary diagnostics?
What is the significance of Zomedica's new 'Crowded Sensor' patent?
